Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 5/20 | 0.48 |
| ▸ | STS | P08842 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | ACP1 | P24666 | 1/20 | 0.44 |
| ▸ | NAMPT | P43490 | 1/20 | 0.43 |
| ▸ | GLS | O94925 | 1/20 | 0.42 |
| ▸ | CXCR3 | P49682 | 2/20 | 0.41 |
| ▸ | CETP | P11597 | 1/20 | 0.41 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.41 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1444654 | 0.91 | STS (0.52) | TACR1STSMAPTGLSCXCR3 | |
| SCHEMBL6863335 | 0.88 | STS (0.56) | TACR1STSMAPTGLSCXCR3 | |
| SCHEMBL26087546 | 0.85 | LMNA (0.45) | MAPTLMNANAMPTGLSCETP | |
| SCHEMBL15844466 | 0.82 | TACR1 (0.44) | TACR1STSMAPTNAMPTGLS | |
| SCHEMBL1444731 | 0.81 | LMNA (0.50) | TACR1MAPTLMNAALDH1A1ACP1 | |
| SCHEMBL6864244 | 0.81 | LMNA (0.45) | TACR1MAPTLMNAALDH1A1ACP1 | |
| SCHEMBL1441503 | 0.80 | MAPT (0.53) | TACR1STSMAPTLMNAALDH1A1 | |
| SCHEMBL6863055 | 0.80 | CACNA1H (0.52) | TACR1MAPTLMNAALDH1A1ACP1 | |
| SCHEMBL26090247 | 0.79 | PRMT5 (0.46) | NAMPT | |
| SCHEMBL26090562 | 0.79 | CACNA1H (0.46) | NAMPTGLSNR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120220564-A1 | SELECTIVE CALCIUM CHANNEL MODULATORS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2012-08-30 | — | — | US | disclosed |
| US-20120220564-A1 | SELECTIVE CALCIUM CHANNEL MODULATORS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2012-08-30 | — | — | US | disclosed |
| WO-2011032291-A1 | SELECTIVE CALCIUM CHANNEL MODULATORS | ZALICUS PHARMACEUTICALS LTD . (CA) | 2011-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120220564-A1 | SELECTIVE CALCIUM CHANNEL MODULATORS | CACNA1G, CACNA1I, CACNA1H | TACR1 441/4885STS 4843/4885MAPT 985/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.